Here we aimed to apply a drug repurposing approach to identify novel candidate drugs for targeting leukemias harboring a rearrangement of the MLL gene, recently renamed KMT2A, present in approximately ten percent of patients with acute leukemia (1–3). Here, KMT2A is linked to acute leukemia.